Cognition Therapeutics, Inc.
NASDAQ:CGTX
0.5202 (USD) • At close November 7, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|
| Revenue
| 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue
| 0.252 | 0.235 | 0.093 | 0.098 | 0.081 |
| Gross Profit
| -0.252 | -0.235 | -0.093 | -0.098 | -0.081 |
| Gross Profit Ratio
| 0 | 0 | 0 | 0 | 0 |
| Reseach & Development Expenses
| 37.196 | 30.324 | 18.572 | 12.887 | 14.379 |
| General & Administrative Expenses
| 13.528 | 13.227 | 10.026 | 4.52 | 3.452 |
| Selling & Marketing Expenses
| -0.252 | 0 | 0 | 0 | 0 |
| SG&A
| 13.528 | 13.227 | 10.026 | 4.52 | 3.452 |
| Other Expenses
| 0 | -22.217 | -17.447 | -10.855 | -13.164 |
| Operating Expenses
| 25.761 | 21.334 | 11.151 | 6.552 | 4.667 |
| Operating Income
| -50.724 | -43.551 | -28.598 | -17.407 | -17.831 |
| Operating Income Ratio
| 0 | 0 | 0 | 0 | 0 |
| Total Other Income Expenses Net
| 24.936 | 22.154 | 16.882 | 9.568 | 12.989 |
| Income Before Tax
| -25.788 | -21.397 | -11.716 | -7.839 | -4.842 |
| Income Before Tax Ratio
| 0 | 0 | 0 | 0 | 0 |
| Income Tax Expense
| 0 | -22.154 | -1.431 | 2.233 | 2.111 |
| Net Income
| -25.788 | 0.757 | -10.285 | -10.072 | -6.953 |
| Net Income Ratio
| 0 | 0 | 0 | 0 | 0 |
| EPS
| -0.86 | 0.026 | -0.46 | -0.46 | -0.32 |
| EPS Diluted
| -0.86 | 0.026 | -0.46 | -0.46 | -0.32 |
| EBITDA
| -50.628 | -21.134 | -13.382 | -5.972 | -3.499 |
| EBITDA Ratio
| 0 | 0 | 0 | 0 | 0 |